Original Research J Clin Psychiatry November 2023

Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series

JCP 2024;85(1):10.4088/JCP.23m15068

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2024;85(1):10.4088/JCP.23m15068 Clinical Summary Alcohol use disorder remains common, morbid, and undertreated, with currently less than 2% of people with AUD in the United States receiving pharmacotherapy using one of these drugs. In this obesity clinic case series, patients started semaglutide for weight loss and all 6 showed marked improvement in alcohol-related symptoms, raising a clinically relevant signal for patients who have both excess weight and hazardous drinking. FAQ What did this case series find about semaglutide and alcohol use disorder symptoms? 10 questions
Key Takeaways The reduction in alcohol-related symptoms was observed across semaglutide doses used for obesity care: 0.25 mg weekly, 0.5 mg weekly, and 1 mg weekly were represented in this series. 6 takeaways Clinical Guide How should clinicians track alcohol use disorder symptoms in patients receiving semaglutide for weight loss? 7 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe